SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.93 Billion KRW | -21.42% |
| 2022 | 5.01 Billion KRW | 1870.95% |
| 2021 | 254.36 Million KRW | -84.77% |
| 2020 | 1.66 Billion KRW | -81.59% |
| 2019 | 9.06 Billion KRW | 17.59% |
| 2018 | 7.71 Billion KRW | 12.34% |
| 2017 | 6.86 Billion KRW | 29.71% |
| 2016 | 5.29 Billion KRW | 192.42% |
| 2015 | 1.8 Billion KRW | -13.23% |
| 2014 | 2.08 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 302.19 Million KRW | -59.16% |
| 2024 Q2 | 806.94 Million KRW | 167.03% |
| 2023 Q3 | 1.71 Billion KRW | -33.78% |
| 2023 FY | 3.93 Billion KRW | -21.42% |
| 2023 Q4 | 739.9 Million KRW | -56.94% |
| 2023 Q1 | 796.34 Million KRW | -18.82% |
| 2023 Q2 | 2.59 Billion KRW | 225.88% |
| 2022 Q2 | 1.13 Billion KRW | 113.25% |
| 2022 FY | 5.01 Billion KRW | 1870.95% |
| 2022 Q1 | 532.53 Million KRW | 2577.64% |
| 2022 Q4 | 980.92 Million KRW | -58.51% |
| 2022 Q3 | 2.36 Billion KRW | 108.19% |
| 2021 Q2 | 2.13 Million KRW | -99.08% |
| 2021 Q4 | 19.88 Million KRW | 8380.62% |
| 2021 FY | 254.36 Million KRW | -84.77% |
| 2021 Q1 | 232.1 Million KRW | -70.91% |
| 2021 Q3 | 234.51 Thousand KRW | -89.03% |
| 2020 FY | 1.66 Billion KRW | -81.59% |
| 2020 Q4 | 797.93 Million KRW | 457.34% |
| 2020 Q3 | 143.16 Million KRW | -72.8% |
| 2020 Q2 | 526.43 Million KRW | 160.38% |
| 2020 Q1 | 202.17 Million KRW | -76.76% |
| 2019 Q3 | 691.86 Million KRW | -88.35% |
| 2019 Q1 | 1.56 Billion KRW | 36.0% |
| 2019 FY | 9.06 Billion KRW | 17.59% |
| 2019 Q4 | 870.11 Million KRW | 25.76% |
| 2019 Q2 | 5.93 Billion KRW | 278.8% |
| 2018 Q2 | 2.06 Billion KRW | -5.35% |
| 2018 Q4 | 1.15 Billion KRW | -49.94% |
| 2018 Q3 | 2.3 Billion KRW | 11.25% |
| 2018 FY | 7.71 Billion KRW | 12.34% |
| 2018 Q1 | 2.18 Billion KRW | -1.13% |
| 2017 Q2 | 1.84 Billion KRW | 5.99% |
| 2017 FY | 6.86 Billion KRW | 29.71% |
| 2017 Q1 | 1.73 Billion KRW | 67.58% |
| 2017 Q4 | 2.21 Billion KRW | 105.8% |
| 2017 Q3 | 1.07 Billion KRW | -41.63% |
| 2016 Q4 | 1.03 Billion KRW | -36.07% |
| 2016 Q2 | 1.17 Billion KRW | -19.81% |
| 2016 Q1 | 1.46 Billion KRW | -5.69% |
| 2016 FY | 5.29 Billion KRW | 192.42% |
| 2016 Q3 | 1.62 Billion KRW | 38.31% |
| 2015 Q3 | -119.66 Million KRW | -151.26% |
| 2015 Q4 | 1.55 Billion KRW | 1395.47% |
| 2015 Q2 | 233.46 Million KRW | 60.11% |
| 2015 Q1 | 145.81 Million KRW | -82.63% |
| 2015 FY | 1.8 Billion KRW | -13.23% |
| 2014 FY | 2.08 Billion KRW | 0.0% |
| 2014 Q2 | 639.36 Million KRW | 204.85% |
| 2014 Q3 | 397.3 Million KRW | -37.86% |
| 2014 Q4 | 839.46 Million KRW | 111.29% |
| 2014 Q1 | 209.73 Million KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | 90.817% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | 58.901% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 97.455% |
| Bioneer Corporation | 263.23 Billion KRW | 98.503% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | 39.394% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 94.261% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | 19.249% |
| Helixmith Co., Ltd | 4.2 Billion KRW | 6.237% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 99.587% |
| Medy-Tox Inc. | 221.12 Billion KRW | 98.218% |
| Peptron, Inc. | 3.34 Billion KRW | -17.884% |
| Amicogen, Inc. | 159.9 Billion KRW | 97.536% |
| Genexine, Inc. | 4.42 Billion KRW | 11.003% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 92.67% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | 88.462% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 95.919% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 98.491% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 93.29% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | 76.913% |
| Genomictree Inc. | 3.41 Billion KRW | -15.259% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | 78.907% |
| EASY BIO,Inc. | 165.38 Billion KRW | 97.618% |
| GI Innovation, Inc. | 5.31 Billion KRW | 25.932% |